Cellzome is a privately-owned drug discovery and development company, and a leader in the use of chemical proteomics technologies to identify a new generation of drug candidates for the treatment of inflammatory diseases.
Our pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for screening and profiling kinases in their physiological context. We have developed a new technology, called Episphere™ to address epigenetic targets in disease-specific protein complexes.
Our goal is to identify oral therapeutics for inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Cellzome has two strategic alliances with GSK to discover, develop and market kinase-targeted therapeutics to treat inflammatory disease and in the emerging field of epigenetics.
© 2013 BioRN Cluster Management GmbH • All Rights Reserved • Contact & Legal Notice